[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO994506L - Methods and compositions for modulating susceptibility to corticosteroids - Google Patents

Methods and compositions for modulating susceptibility to corticosteroids

Info

Publication number
NO994506L
NO994506L NO994506A NO994506A NO994506L NO 994506 L NO994506 L NO 994506L NO 994506 A NO994506 A NO 994506A NO 994506 A NO994506 A NO 994506A NO 994506 L NO994506 L NO 994506L
Authority
NO
Norway
Prior art keywords
agent
corticosteroid
subject
preferred
antagonist
Prior art date
Application number
NO994506A
Other languages
Norwegian (no)
Other versions
NO994506D0 (en
Inventor
Les Sekut
Adam Carter
Tariq Ghayur
Subhashis Banerjee
Daniel E Tracey
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO994506D0 publication Critical patent/NO994506D0/en
Publication of NO994506L publication Critical patent/NO994506L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Fremgangsmåte for å modulere mottageligheten for kortikosteroider i et individ er fremskaffet, l fremgangsmåten i oppfinnelsen blir en agens, som antagoniserer et mål som regulerer produksjon av IFN-y i individet, administrert til individet i kombinasjon med et kortikosteroid slik at individets mottagelighet for kortikosteroidet blir modulert sammenlignet med når et kortikosteroid blir administrert alene til individet, l en utførelse er agenser en IL-18-antagonist. l en annen utførelse er agensen en interleukin-12 (IL-12)-antagonist. l ytterligere en annen utførelse er agensen en NK-celleantagonist. l en foretrukket utførelse er agensen en inhibitor for en kaspasefamilieprotease, fortrinnsvis en ICE-inhibitor. l en annen foretrukket utførelse er agensen et anti-IL-12 monoklonalt antistoff, l ytterligere en annen foretrukket utførelse er agensen et anti-asialo-GM1-antistoff eller et NK1.1-antistoff. Andre foretrukkede agenser innbefatter fosfodiesterase IV inhibitorer og beta-2 agonister. Fremgangsmåtene i oppfinnelsen kan anvendes i behandlingen av en rekke inflammatoriske og immunologiske sykdommer og lidelser. Farmasøytiske blandinger innbefattende en agens som antagoniserer et mål som regulerer produksjon av IFN-y i et individ, et kortikosteroid og en farmasøytisk godkjent bærer er også tilveiebragt. En foretrukket blanding innbefatter en ICE-inhibitor, et kortikostorpid og en farmasøytisk godkjent bærer.A method of modulating susceptibility to corticosteroids in an individual is provided, in the method of the invention, an agent which antagonizes a target which regulates the production of IFN-γ in the subject is administered to the subject in combination with a corticosteroid so that the subject's susceptibility to the corticosteroid becomes modulated compared to when a corticosteroid is administered alone to the subject, in one embodiment, agents are an IL-18 antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In yet another embodiment, the agent is an NK cell antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody, in yet another preferred embodiment, the agent is an anti-asialo-GM1 antibody or an NK1.1 antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions including an agent that antagonizes a target that regulates the production of IFN-γ in an individual, a corticosteroid and a pharmaceutically approved carrier are also provided. A preferred composition includes an ICE inhibitor, a corticostorphide and a pharmaceutically approved carrier.

NO994506A 1997-03-18 1999-09-17 Methods and compositions for modulating susceptibility to corticosteroids NO994506L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US1634698A 1998-01-30 1998-01-30
PCT/US1998/004916 WO1998041232A2 (en) 1997-03-18 1998-03-12 Compositions for modulating responsiveness to corticosteroids

Publications (2)

Publication Number Publication Date
NO994506D0 NO994506D0 (en) 1999-09-17
NO994506L true NO994506L (en) 1999-11-17

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994506A NO994506L (en) 1997-03-18 1999-09-17 Methods and compositions for modulating susceptibility to corticosteroids

Country Status (20)

Country Link
EP (1) EP0998300A1 (en)
JP (1) JP2002504091A (en)
KR (1) KR20000076420A (en)
CN (1) CN1269722A (en)
AU (1) AU734756B2 (en)
BG (1) BG103808A (en)
BR (1) BR9810409A (en)
CA (1) CA2282845A1 (en)
DE (1) DE998300T1 (en)
ES (1) ES2146192T1 (en)
HU (1) HUP0104439A3 (en)
ID (1) ID22975A (en)
IL (1) IL131815A0 (en)
NO (1) NO994506L (en)
NZ (1) NZ337769A (en)
PL (1) PL336464A1 (en)
SI (1) SI20110A (en)
SK (1) SK122199A3 (en)
TR (1) TR199902615T2 (en)
WO (1) WO1998041232A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (en) * 1997-10-17 2001-05-30 Smithkline Beecham Corp USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
CA2276420A1 (en) * 1997-10-31 1999-05-14 Terry Strom Use of anti-il-12 antibodies in transplantation rejection
WO1999025737A1 (en) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
KR20010041905A (en) * 1998-03-16 2001-05-25 시토비아 인크. Dipeptide caspase inhibitors and the use thereof
WO2001045747A1 (en) * 1998-11-27 2001-06-28 Technion Research & Development Foundation Ltd. Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis
DE69927520T2 (en) * 1998-12-09 2006-06-22 Protein Design Labs, Inc., Fremont USE OF IL-12 ANTIBODIES FOR THE TREATMENT OF PSORIASIS
CA2367340A1 (en) 1999-03-16 2000-09-21 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DE19915465A1 (en) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Use of a caspase inhibitor to inhibit cell proliferation and use of one or more caspase inhibitors to treat diseases based on lymphocyte hyperproliferation or to suppress an immune response by lymphocytes
ATE363465T1 (en) 1999-04-09 2007-06-15 Cytovia Inc CASPASE INHIBITORS AND THEIR USE
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
ATE409688T1 (en) 1999-08-27 2008-10-15 Cytovia Inc SUBSTITUTED ALPHA-HYDROXY ACIDS AS CASPASE INHIBITORS AND THEIR USE
AU7127600A (en) * 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AU2001236807A1 (en) 2000-02-10 2001-08-20 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
EP1289557B1 (en) * 2000-06-06 2006-07-12 Glaxo Group Limited Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
WO2001097815A2 (en) * 2000-06-22 2001-12-27 Willy Ben Moussa Ben Mohammed Use of glucocorticosteroids for producing a medicament to treat oligotrichia
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EA006767B1 (en) * 2001-01-29 2006-04-28 Апплайд Резеч Системз Арс Холдинг Н.В. Use of il-18 inhibitors for preparing a medicament for the treatment and/or prevention of heart disease
BR0210904A (en) * 2001-05-16 2005-08-16 Yeda Res & Dev Use of il-18 inhibitors for the treatment or prevention of sepsis.
CN1547486A (en) 2001-06-26 2004-11-17 Antibodies to OPGL
EP2279742A3 (en) * 2001-10-05 2011-04-20 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
JP2003342196A (en) * 2002-05-31 2003-12-03 Mukku:Kk Composition for intravenous injection, method of production for the same and its preparation
JP2006503905A (en) * 2002-09-24 2006-02-02 コンビナトアールエックス インコーポレーティッド Methods and reagents for the treatment of diseases and disorders associated with increased levels of inflammatory cytokines
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
EP1752159A4 (en) * 2004-05-17 2009-07-01 Univ Keio Medicinal composition and therapeutic method
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DK1808446T3 (en) * 2004-07-16 2012-05-14 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
WO2006041121A1 (en) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for chronic skin disease
EP2397034A1 (en) 2005-07-14 2011-12-21 Lithera, Inc. Sustained Release Enhanced Lipolytic Formulation for Regional Adipose Tissue Treatment
ES2398480T3 (en) * 2006-10-17 2013-03-19 Lithera, Inc. Procedures, compositions, and formulations for the treatment of thyroid eye disease
KR20150038227A (en) 2007-01-16 2015-04-08 애브비 인코포레이티드 Methods for treating psoriasis
EP2142565A4 (en) 2007-03-29 2010-03-31 Abbott Lab Crystalline anti-human il-12 antibodies
EP2274333A4 (en) 2008-03-18 2011-06-15 Abbott Lab Methods for treating psoriasis
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
MX2013005873A (en) 2010-11-24 2013-08-07 Lithera Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging.
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
WO2022173923A1 (en) 2021-02-10 2022-08-18 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
US20230090417A1 (en) * 2021-09-22 2023-03-23 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
ATE92762T1 (en) * 1989-09-08 1993-08-15 Glaxo Group Ltd MEDICATION.
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (en) * 1992-07-31 1994-03-31 Glaxo Group Ltd PHARMACEUTICAL FORMULATION IN AEROSOL, CAN SUITABLE TO RELEASE THE FORMULATION AND INHALER OF DOSE DOSE THAT COMPRISES THE CAN.
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
CN1186473A (en) * 1995-04-14 1998-07-01 葛兰素惠尔康公司 Metered dose inhaler for beclomethasone dipropionate

Also Published As

Publication number Publication date
AU734756B2 (en) 2001-06-21
SK122199A3 (en) 2000-12-11
ES2146192T1 (en) 2000-08-01
NO994506D0 (en) 1999-09-17
AU6760498A (en) 1998-10-12
DE998300T1 (en) 2001-03-01
HUP0104439A3 (en) 2002-08-28
HUP0104439A2 (en) 2002-04-29
TR199902615T2 (en) 2000-03-21
CN1269722A (en) 2000-10-11
BR9810409A (en) 2000-08-22
CA2282845A1 (en) 1998-09-24
KR20000076420A (en) 2000-12-26
WO1998041232A2 (en) 1998-09-24
IL131815A0 (en) 2001-03-19
BG103808A (en) 2000-07-31
PL336464A1 (en) 2000-06-19
EP0998300A1 (en) 2000-05-10
NZ337769A (en) 2002-09-27
ID22975A (en) 1999-12-23
JP2002504091A (en) 2002-02-05
SI20110A (en) 2000-06-30
WO1998041232A3 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
NO994506L (en) Methods and compositions for modulating susceptibility to corticosteroids
Bearn et al. The problem of chronic liver disease in young women
WO2001019373A3 (en) Methods and compositions for modulating responsiveness to corticosteroids
Adamopoulos et al. Pituitary-testicular interrelationships in mumps orchitis and other viral infections
Axelrod et al. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout
Williamson et al. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon.
Burris et al. A low sperm concentration does not preclude fertility in men with isolated hypogonadotropic hypogonadism after gonadotropin therapy
Puig-Domingo et al. Melatonin-related hypogonadotropic hypogonadism
US6180355B1 (en) Method for diagnosing and treating chronic pelvic pain syndrome
MANN et al. Long‐term administration of corticosteroids in myasthenia gravis
Durham et al. Immunotherapy and allergic inflammation.
Nelson Prophylaxis of VTE in women–during assisted reproductive techniques
Reinberg et al. Annual variation in semen characteristics and plasma hormone levels in men undergoing vasectomy
Chen et al. Persistent effect of in utero meso-2, 3-dimercaptosuccinic acid (DMSA) on immune function and lead-induced immunotoxicity
KAY et al. Immunofluorescent techniques in clinical diagnosis of cutaneous disease
Nissinen et al. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis
Brooks-Asplund et al. Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women
Homonnai et al. Phenoxybenzamine—an effective male contraceptive pill
De Merieux et al. Treatment of Behcet's syndrome with levamisole
JP2006516617A (en) Combination of IL-6 antagonist and steroid to enhance apoptosis
Sauer et al. Rare occurrence of ovarian hyperstimulation syndrome in oocyte donors
CA2296409A1 (en) Agents comprising midkine or its inhibitor as active ingredient
De Almeida et al. Dexamethasone therapy of infertile men with sperm autoantibodies: immunological and sperm follow-up.
Nutku et al. Evidence for expression of eosinophil-associated IL-12 messenger RNA and immunoreactivity in bronchial asthma
Heiligenhaus et al. Eosinophil granule proteins expressed in ocular cicatricial pemphigoid